维普中文期刊产品整合服务
20篇 您的检索式:作者名="Troconiz"
    题名 作者 年代 出处 被引量
1Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months显示文摘Troconiz IF Cendros JM Peraire C 2009Clin Pharmacokinet2009,48,1:1
2Pharmacokinetic pharmacodynamic modeling of the in?uence of chronic phenytoin therapyon the rocuronium bromide response in patients undergoing brain surgery显示文摘Femandez-Candil J Gambus PL Troconiz IF 2008Eur J Clin Pharmacol2008,64,8:1
3Pharmacokinetic-pharmacodynamic modeling in anesthesia显示文摘GAMBUS P L TROCONIZ I F 2001Int Congr Series2001,1220,:1
4Methadone: a review of its pharmacokinetic/pharmacodynamic properties 显示文摘GARRIDO M J TROCONIZ IF 1999J Pharmacol Toxicol1999,42,2:1
5Feasibility of microdialysis to determine interstitial rocuronium concentration in the muscle tissue of anesthetized neurosurgical patients显示文摘FERNANDEZ-CANDIL J GAMBUS P L TROCONIZ I F 2010J Neurosurg Anesthesiol2010,22,2:1
6Methadone: a review of its pharmacokinetic/pharmacodynamic properties显示文摘Grrido MJ Troconiz IF 1999J Pharmacol Toxicol Methods1999,42,2:1
7Modelling the anti- migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist显示文摘Troconiz I F Wolters J M Tillmann C 2006Clin Pharmacokinet2006,45,7:1
8Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents 显示文摘Moreno D Troconiz IF Enguita M 2008J Pharm Pharmaco12008,60,1:1
9Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents显示文摘Moreno D Troconiz IF Enguita M 2008J Pharm Pharmacol2008,60,1:1
10Semi--mechanistic description of the in--vitro antiproliferative effect of different antitumour agents显示文摘Moreno D Troconiz IF Enguita M 2008J Pharm Pharmacol2008,60,1:1
11Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents显示文摘Moreno D Troconiz IF Enguita M 2008J Pharm Pharmacol2008,60,1:1
12Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours显示文摘TROCONIZ IF GARRIDO MJ SEGURA C 2006Cancer Chemother Pharmacol2006,57,6:1
13Predictive 'ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents:two case studies 显示文摘SOTO E KE1ZER R J TROCONIZ I F 2011Invest New Drugs2011,29,:1
14Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy显示文摘Isla A Rodrtguez- Gascon A Troconiz I F 2008Clin Pharmacokinet2008,47,3:1
15Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility显示文摘De SPC Campanero MA Troconiz IF 2004Int J Pharm2004,270,12:1
16Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents显示文摘Moreno D Troconiz IF Enguita M 0,,01:1
17Modeling theinfluence of the A118G polymorphism in the OPRM1gene and of noxious stimulation on the synergistic relationbetween propofol and remifentanil: sedation and analgesiain endoscopic procedures 显示文摘Borrat X Troconiz IF Valencia JF 2013Anesthesiology2013,118,6:1
18The influence of age on the dynamic relationship between end-tidal sevoflurane con- centrations and bispectral index显示文摘Cortinez L I Troconiz I F Fuentes R 2008Anesth Analg2008,107,5:1
19Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate(BIBR 1048) in patients undergoing primary elective total hip replacement surgery显示文摘Troconiz IF 2007J Clin Pharmacol2007,47,3:1
20七氟醚浓度和BIS指数的“滞后”效应测量显示肥胖不影响七氟醚作用起效和消除显示文摘背景肥胖患者的呼吸以及气体交换的生理改变可能导致麻醉气体作用的起效和消除延迟。本研究评估了肥胖对七氟醚及BIS值之间“滞后”效应的影响。因为呼气末正压(positiveend-expiratorypressure,PEEP)可改善肥胖患者的气体交换,所以我们也同时评估了PEEP对该“滞后”效应的影响。方法前瞻性研究了15例肥胖和15例体重正常的ASAI级和Ⅱ级、20-50岁、择期行全麻下腹腔镜手术的患者。麻醉诱导使用丙泊酚,维持使用七氟醚和芬太尼。手术结束后将BIS值维持稳定在60~65,然后将七氟醚吸入浓度增加至5v01%,持续5分钟或至BIS〈40为止,然后降低吸入浓度。正常体重患者七氟醚浓度变换一次(无PEEP),肥胖患者浓度变换两次(一次无PEEP,一次PEEP=8cm H2O)。七氟醚浓度变换期间七氟醚呼末浓度和BIS之间的“滞后”效应通过抑制性Emax模型建模,使用的是NONEMN(非线性混合效应模型)第VI版的群体药代动力学/药效动力学(pharmacokinetic/pharmacodynamic.PK/PD)方法。对七氟醚吸入和呼出浓度、BIS值和达不同BIS终点的时间等指标的描述性分析也被用于比较PK和PD特征。结果所有患者均完成研究。数据完全符合PK/PD模型。体重指数或PEEP对“滞后”效应无影响(P〉0.05),“滞后”效应使用效应室消除率常数表示。肥胖和PEEP均未显示对PK/PD的相关指标有影响。结论结果未显示七氟醚(低血溶解度麻醉药)吸入麻醉90~120分钟后肥胖患者的诱导或恢复时间将延长。Luis I. Cortinez, MD Pedro Gambtus, MD, Inaki F. Troconiz, PhD Ghislaine Echevarria, MD Hernan R. Munoz, MD, MSc 杨定东(译) 王绍林(校) 刘小彬(校) 2013麻醉与镇痛2013,,6:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费